Picture courtesy The Indian Express
Pune: Serum Institute of India (SII) has sought emergency use authorisation (EUA) for its COVID-19 vaccine Covovax for the 12-17 age group.
Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, stated in the application that data from two studies on 2,707 children aged 12 to 17 years show that Covovax is highly efficacious, immunogenic, safe and well-tolerated in this age group, The Indian Express reported quoting official sources.
The Drugs Controller General Of India (DCGI) has already approved Covovax for emergency use among adults.
Covovax is produced in India by Pune-based Serum Institute through technology transfer from American biotechnology company Novavax.
Earlier today, DCGI granted emergency use approval to Biological E’s indigenous vaccine Corbevax for children aged 12 to 17 years.
Currently, only those in the 15-17 year age group are being inoculated in India.
Mumbai: Television actress Hina Khan, who is battling breast cancer, recently met host Salman Khan…
Mumbai: Following reports of his alleged link-up with bassist Mohini Dey, renowned music composer AR…
Mumbai: The love story of actors Tamannaah Bhatia and Vijay Varma has not been clandestine.…
Puri: Shree Jagannath Temple Administration (SJTA) has received the report of the Ratna Bhandar’s GPR-GPS…
With his debut novel ‘The Other Side of the Rainbow’ published recently, Niranjan Nayak, an…
Bhubaneswar: Odisha outplayed Chhattisgarh 4-1 on Saturday to seal a berth in the final round…
Mumbai: The Telangana government’s notice barring him from singing songs promoting alcohol and drugs at…
Bhubaneswar: Prime Minister Narendra Modi will participate in the ‘Odisha Parba 2024’ programme on Sunday…